Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 30.00%, near the low end of its 5-year range (0.00%–350.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 10.00%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
10.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
30.00%
GROSS MARGIN AVG 10Y
36.60%
GROSS MARGIN AVG 15Y
51.35%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
-100.00%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.76%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Benitec Biopharma Inc.
Market Cap
$304.88M
Gross Margin
0.00%
TTM Avg
10.00%
3Y Avg
0.00%
5Y Avg
30.00%
Market Cap
$309.45M
Gross Margin
49.14%
TTM Avg
49.09%
3Y Avg
45.86%
5Y Avg
49.48%
Market Cap
$316.53M
Gross Margin
81.07%
TTM Avg
81.07%
3Y Avg
81.07%
5Y Avg
81.07%
Market Cap
$290.87M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$285.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$285.98M
Gross Margin
73.68%
TTM Avg
36.84%
3Y Avg
49.00%
5Y Avg
66.00%
Market Cap
$328.40M
Gross Margin
77.81%
TTM Avg
88.91%
3Y Avg
85.13%
5Y Avg
50.71%
Market Cap
$281.16M
Gross Margin
0.00%
TTM Avg
10.38%
3Y Avg
-887.42%
5Y Avg
-730.43%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $304.88M | 0.00% | 10.00% | 0.00% | 30.00% |
| Standard BioTools Inc. (LAB)vs › | $309.45M | 49.14% | 49.09% | 45.86% | 49.48% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $316.53M | 81.07% | 81.07% | 81.07% | 81.07% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | 0.00% | 0.00% | 0.00% | 0.00% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $285.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| CapsoVision, Inc. (CV)vs › | $323.01M | 50.88% | 53.58% | 54.49% | 54.49% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.98M | 73.68% | 36.84% | 49.00% | 66.00% |
| C4 Therapeutics, Inc. (CCCC)vs › | $328.40M | 77.81% | 88.91% | 85.13% | 50.71% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | 0.00% | 10.38% | -887.42% | -730.43% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 50.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 350.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 50.00% |
| 2021-03-31 | -600.00% |
| 2020-12-31 | 2000.00% |
| 2020-09-30 | -143.64% |
| 2020-06-30 | 220.00% |
| 2020-03-31 | -67.86% |
| 2019-12-31 | 497.40% |
| 2019-09-30 | 21.21% |
| 2019-06-30 | 95.33% |
| 2019-03-31 | 94.64% |
| 2018-12-31 | 96.58% |
| 2018-09-30 | 96.60% |
| 2018-06-30 | -1.08% |
| 2018-03-31 | -57.02% |
| 2017-12-31 | 52.85% |
| 2017-09-30 | 73.02% |
| 2017-06-30 | 123.50% |
| 2017-03-31 | 23.34% |
| 2016-12-31 | 30.44% |
| 2016-09-30 | 80.18% |
| 2016-06-30 | 16.20% |
| 2016-03-31 | 58.89% |
| 2015-12-31 | 61.56% |
| 2015-09-30 | 63.65% |
| 2015-06-30 | 99.98% |
| 2015-03-31 | 91.94% |
| 2014-12-31 | 93.74% |
| 2014-09-30 | 93.74% |
| 2014-06-30 | 83.71% |
| 2014-03-31 | 83.71% |
| 2013-12-31 | 97.50% |
| 2013-09-30 | 97.50% |
| 2013-06-30 | 100.00% |
| 2013-03-31 | 100.00% |
| 2012-12-31 | 95.00% |
| 2012-09-30 | 95.00% |
